Search
Bright Minds Biosciences Inc
DRUGAdd to Watchlist
73.260USD
-1.370-1.84%
Close 07-31 16:00（ET）Quotes delayed by 15 min
721.85MMarket Cap
LossP/E TTM
More Details of Bright Minds Biosciences Inc Company
Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
Bright Minds Biosciences Inc Info
Ticker SymbolDRUG
Company nameBright Minds Biosciences Inc
IPO dateFeb 08, 2021
CEOMcdonald (Ian B)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 08
Address19 Vestry Street
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10013
Phone16478658622
Websitehttps://brightmindsbio.com/
Ticker SymbolDRUG
IPO dateFeb 08, 2021
CEOMcdonald (Ian B)
Company Executives of Bright Minds Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jeremy Fryzuk
Mr. Jeremy Fryzuk
Independent Director
Independent Director
38.11K
+45.92%
Mr. Nils Christian Bottler
Mr. Nils Christian Bottler
Independent Director
Independent Director
7.50K
+33.33%
Mr. Ian B. Mcdonald
Mr. Ian B. Mcdonald
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Ryan Cheung
Mr. Ryan Cheung
Chief Financial Officer
Chief Financial Officer
--
--
Dr. David M. Weiner
Dr. David M. Weiner
Independent Director
Independent Director
--
--
Dr. Jan Pedersen
Dr. Jan Pedersen
Chief Scientific Officer, Director
Chief Scientific Officer, Director
--
--
Dr. Stephen D. Collins, M.D., Ph.D.
Dr. Stephen D. Collins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jeremy Fryzuk
Mr. Jeremy Fryzuk
Independent Director
Independent Director
38.11K
+45.92%
Mr. Nils Christian Bottler
Mr. Nils Christian Bottler
Independent Director
Independent Director
7.50K
+33.33%
Mr. Ian B. Mcdonald
Mr. Ian B. Mcdonald
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Ryan Cheung
Mr. Ryan Cheung
Chief Financial Officer
Chief Financial Officer
--
--
Dr. David M. Weiner
Dr. David M. Weiner
Independent Director
Independent Director
--
--
Dr. Jan Pedersen
Dr. Jan Pedersen
Chief Scientific Officer, Director
Chief Scientific Officer, Director
--
--
FAQs
Who are the top five shareholders of Bright Minds Biosciences Inc?
The top five shareholders of Bright Minds Biosciences Inc are: Mr. Jeremy Fryzuk
How many institutions hold shares of Bright Minds Biosciences Inc (DRUG)?
As of 2026Q1, 137 institutions hold shares of Bright Minds Biosciences Inc, with a combined market value of approximately 6.71M, accounting for 68.61% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -102671.00.